|
Inherited Factor II deficiency
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Prophylactic administration of prothrombin complex concentrates for congenital prothrombin deficiency with a novel frameshift mutation, prothrombin saitama.
|
23152198 |
2013 |
|
Inherited Factor II deficiency
|
0.800 |
Biomarker
|
disease |
BEFREE |
Automated fluorescence-based DNA sequence analysis of amplified genomic DNA was used to define prothrombin gene regions from a patient with severe functional hypoprothrombinemia and little detectable prothrombin antigen.
|
9351523 |
1997 |
|
Inherited Factor II deficiency
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Cases with a parallel decrease in prothrombin activity and antigen should not be considered as examples of hypoprothrombinemia.
|
9863703 |
1998 |
|
Inherited Factor II deficiency
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A patient with a severe bleeding tendency and hypoprothrombinemia (Factor II activity 2%, Factor II antigen 5%) was screened for the presence of alterations in his prothrombin gene.
|
7740448 |
1994 |
|
Inherited Factor II deficiency
|
0.800 |
Biomarker
|
disease |
BEFREE |
The primary effect of this defect appears to be destabilization of the circulating prothrombin, creating a moderate hypoprothrombinemia.
|
14629473 |
2003 |
|
Inherited Factor II deficiency
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The abnormal prothrombin gene of an Italian patient with a severe bleeding tendency and hypoprothrombinemia was selected for study and compared with the prothrombin genes of healthy controls.
|
9134629 |
1997 |
|
Inherited Factor II deficiency
|
0.800 |
Biomarker
|
disease |
BEFREE |
Molecular and genetic analysis of a compound heterozygote for dysprothrombinemia of prothrombin Tokushima and hypoprothrombinemia.
|
1334372 |
1992 |
|
Inherited Factor II deficiency
|
0.800 |
Biomarker
|
disease |
BEFREE |
Prothrombin (factor II) deficiency is a rare autosomal recessive coagulation disorder that occurs in approximately 1 in 1-2 million people.
|
19141155 |
2008 |
|
Inherited Factor II deficiency
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Hypoprothrombinemia (OR 1.676, 95% CI 1.275-2.203) and prothrombin time (PT) prolongation (OR 2.050, 95% CI 1.398-3.005) were significantly associated with NMTT-cephalosporins, whereas bleeding was not (OR 1.359, 95% CI 0.920-2.009).
|
31623191 |
2019 |
|
Disseminated Intravascular Coagulation
|
0.600 |
Biomarker
|
disease |
BEFREE |
We used the modified ISTH score for DIC, which is based on platelet count, fibrinogen concentration, and prothrombin time (PT) differences.
|
29065752 |
2019 |
|
Disseminated Intravascular Coagulation
|
0.600 |
Biomarker
|
disease |
BEFREE |
Abbreviations: AML: acute myeloid leukemia; APL: acute promyelocytic leukemia; WBC: white blood cell; RBC: red blood cell; Hb: hemoglobin; PT: prothrombin time; TT: thrombin time; APTT: activated partial thromboplastin time; TP: total protein; ALB: albumin; AST: aspartate transaminase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase; ATRA: all-trans retinoic acid; ICH: intracranial hemorrhage; DIC: disseminated intravascular coagulation.
|
30453810 |
2019 |
|
Disseminated Intravascular Coagulation
|
0.600 |
Biomarker
|
disease |
BEFREE |
Potential factors influencing adverse maternal outcome were male fetus (p = 0.04), postpartum diagnosis of AFLP (p < 0.01), intrauterine fetal death (p = 0.04), disseminated intravascular coagulation (p < 0.01), prothrombin time (p < 0.01) and activated partial thromboplastin time (p = 0.04).
|
29297090 |
2018 |
|
Disseminated Intravascular Coagulation
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
From medical records, we collected information about the following coagulation and fibrinolytic factors at hospital admission: platelet count; prothrombin time; activated partial thromboplastin time; plasma levels of fibrinogen, D-dimer, fibrin/fibrinogen degradation products (FDP), and antithrombin; and calculated DIC score.
|
27940211 |
2017 |
|
Disseminated Intravascular Coagulation
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The disseminated intravascular coagulation (DIC) score, which is based on readily available and relatively inexpensive coagulation parameters, including platelet count, fibrin-related markers, prothrombin time and fibrinogen, has not been reported regarding PVT development in cirrhotic patients to date.
|
29178991 |
2018 |
|
Disseminated Intravascular Coagulation
|
0.600 |
Biomarker
|
disease |
BEFREE |
We examined whether a dual short-acting thrombin (factor II) and factor X (FX)a inhibitor (SATI) ameliorates sepsis-induced disseminated intravascular coagulation (DIC) and is organ-protective.
|
28288667 |
2017 |
|
Disseminated Intravascular Coagulation
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prothrombin Complex Concentrate-induced Disseminated Intravascular Coagulation Can Be Prevented by Coadministering Antithrombin in a Porcine Trauma Model.
|
31180918 |
2019 |
|
Disseminated Intravascular Coagulation
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Secondary outcomes included platelet count, disseminated intravascular coagulation (DIC), and prothrombin time (PT).
|
30064685 |
2018 |
|
Disseminated Intravascular Coagulation
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prothrombin time (PT) with international normalized ratio (INR) was estimated at similar intervals to detect venom-induced consumption coagulopathy.
|
30918965 |
2019 |
|
Disseminated Intravascular Coagulation
|
0.600 |
Biomarker
|
disease |
BEFREE |
Laboratory measurement of prothrombin fragment 1.2, a byproduct of prothrombin conversion to thrombin, proved to be a useful way to monitor this patient's DIC over time.
|
30461646 |
2018 |
|
Disseminated Intravascular Coagulation
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, treatment with rTM significantly improved DIC score, fibrinogen, fibrin/fibrinogen degradation product (FDP), and prothrombin time (PT) ratio.
|
30383650 |
2018 |
|
Disseminated Intravascular Coagulation
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In Swiss albino mice, intraperitoneal injection of PAF causes sudden death with oxidative stress and disseminated intravascular coagulation (DIC), characterized by prolonged prothrombin time, thrombocytopenia, reduced fibrinogen content, and increased levels of fibrinogen degradation products.
|
31442556 |
2019 |
|
Disseminated Intravascular Coagulation
|
0.600 |
Biomarker
|
disease |
BEFREE |
Group 1 and 2 animals developed features of disseminated intravascular coagulation (DIC), with reductions of fibrinogen and platelets and increases of prothrombin time, partial thromboplastin time, and fibrin split products.Graft survival was for 6-13 days.
|
11740383 |
2001 |
|
Disseminated Intravascular Coagulation
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
DIC, defined as platelet counts below 100 G L(-1), increased D-dimer levels and prolonged prothrombin time, was significantly associated with the 4G4G genotype [31 of 63 (49%) vs. 55 of 175 (31%), P = 0.014], resulting in a hazard ratio (HR) of 1.5 (95% confidence interval 1.1-2.1) to develop DIC.
|
17697137 |
2007 |
|
Thrombophilia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Factor V Leiden (FVL) and prothrombin gene (G20210A) mutations are the most common types of hereditary thrombophilias, but are usually undiagnosed because most carriers are asymptomatic.
|
15006834 |
2004 |
|
Thrombophilia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease.
|
9409210 |
1997 |